Logo
    Search

    Podcast Summary

    • Ozempic and similar drugs causing a stir for weight loss capabilitiesGLP-1 class drugs, initially for blood sugar regulation, induce weight loss as a side effect, gaining popularity due to obesity being a major public health concern and cultural interest in weight loss solutions

      Ozempic and similar drugs are causing a significant stir in both the medical and cultural spheres due to their effective weight loss capabilities. These drugs, which belong to the GLP-1 class, were initially developed to regulate blood sugar and insulin but were found to induce weight loss as a side effect. With obesity being a major public health concern and a cultural conversation around body image ongoing, the arrival of Ozempic and similar drugs has introduced a new dimension to these discussions. The drug's widespread popularity, as evidenced by its prevalence in social media and advertising, highlights the growing interest and need for effective weight loss solutions.

    • Ozempic's ability to aid weight lossOzempic, used for type 2 diabetes, aids significant weight loss by mimicking a hormone and targeting appetite regulation areas. However, its high demand for weight management has led to shortages for those who need it for diabetes.

      The once-weekly injectable drug Ozempic, approved for type 2 diabetes, has been found to help people lose significant weight. This occurs due to the medication's ability to mimic a naturally occurring hormone, making users feel fuller for longer and targeting the brain's appetite regulation areas. However, if stopped, the weight loss may be reversed. The FDA approved Wegovy for weight management in 2021, leading to increased demand for Ozempic as a weight loss alternative. Despite not being officially approved for weight loss, many people and doctors seek it out, often paying high out-of-pocket costs due to insurance limitations. The high demand has led to drug shortages for those who genuinely need it for diabetes management.

    • Discovering Weight Loss Drugs on Social MediaSocial media and celebrity endorsements have shifted the focus of weight loss drugs from managing diabetes to weight loss, potentially overshadowing their original purpose and leading to a damaging emphasis on thinness.

      The popularity of weight loss drugs like Ozempic and Wegovy has skyrocketed due to social media buzz and celebrity endorsements, shifting the focus from managing diabetes to weight loss. This trend raises important questions about our society's relationship with weight and health. For instance, Wendy Gant, a mental health counselor in her fifties, discovered these drugs on TikTok and saw them as a potential solution to her lifelong struggle with weight. She had tried numerous diets since childhood and, as an adult, her weight issue became a medical concern when her cholesterol levels rose. Another woman, whose story will be shared later, also experienced significant life changes after taking these drugs. The mainstream conversation around these medications is now primarily centered on weight loss, which could potentially overshadow their original purpose. It's crucial to strike a balance between promoting health and avoiding the psychologically damaging emphasis on being excessively thin. As these drugs become more prevalent, individuals taking them must grapple with the implications and meaning behind their use.

    • Manjaro helps quiet the constant mental chatter around foodManjaro medication can bring significant relief from constant food preoccupation, leading to increased success in implementing healthy habits and substantial weight loss

      For some individuals, particularly those struggling with weight despite diet and exercise efforts, the medication Manjaro (similar to Ozempic) can bring about a significant shift in their relationship with food. This shift is described as a quieting of the constant mental chatter around food, allowing individuals to focus on other aspects of their health and wellbeing. This relief can lead to increased success in implementing long-term healthy habits, resulting in substantial weight loss. For instance, the woman in the discussion lost 40 pounds after beginning the medication. This transformation can be compared to the reduction in anxiety noise experienced by those taking antianxiety medication. Overall, Manjaro offers a promising solution for those seeking to improve their relationship with food and achieve weight loss goals.

    • Two women, two different weight loss journeysEvery weight loss journey is unique, with some finding relief through medication while others focus on intuitive eating, ultimately leading to self-acceptance and peace with their bodies.

      While weight loss medications can bring significant physical improvements for some individuals, the experience is not the same for everyone. For Wendy, a medication for her arthritis led to a 20% weight loss and alleviation of her joint pain. However, she doesn't grapple much with the larger questions of self-acceptance and body positivity. In contrast, Renata, diagnosed with PCOS, found relief through intuitive eating, which helped her stop dieting and focus on foods that made her feel good. Her journey led her to peace with her body, but a doctor's visit introduced her to a weight loss medication she hadn't sought out. Both women's stories illustrate that weight loss journeys are complex and multifaceted, and there's no one-size-fits-all solution.

    • Personal determination to stick with medication despite side effectsIndividuals may continue taking medications despite severe side effects, emphasizing the importance of being informed and the resilience shown in managing health.

      Renata, unlike some people, relies on her doctor's advice to try new medications, even when the side effects are severe. In this case, she began taking Ozempic for weight loss and experienced extreme nausea and difficulty digesting food. Despite feeling sick and having a hard time eating, she continued taking the medication due to the investment she had made and the belief that it could eventually benefit her. Unfortunately, the medication caused her to become malnourished due to her inability to eat enough. This experience highlights the importance of being informed about medications and their potential side effects, as well as the determination and resilience that some individuals show in managing their health despite challenges.

    • Unexpected challenges with weight loss medicationsWeight loss medications like Ozempic can lead to unexpected challenges such as malnourishment and a complicated relationship with food. Individuals must weigh the risks and benefits before deciding to continue or discontinue use.

      The use of weight loss medications like Ozempic can bring about unexpected challenges, including malnourishment and a complicated relationship with food. Renata's experience of losing little weight while struggling with appetite and nutrient intake was starkly different from Wendy's reported success. Although malnourishment is rare, it highlights the potential side effects that individuals may face when deciding to use these medications. The decision to continue or discontinue use depends on the individual's assessment of the risks and benefits. Renata's experience of becoming preoccupied with food while on the medication led her to question her progress in separating her self-worth from her weight. This shift in perspective, while intended to promote weight loss, ultimately complicated her relationship with food and her mental health. The widespread use of these medications underscores a significant cultural shift in attitudes towards weight and obesity, moving away from viewing it as a moral failing and towards a more nuanced understanding of health and wellness.

    • The moral implications of weight loss medicationsWeight loss medications like Ozempic raise moral questions, offering potential solutions to obesity while reinforcing societal expectations of thinness and creating new layers of stigma

      The availability of weight loss medications like Ozempic raises complex questions about morality, personal choice, and societal stigma surrounding obesity. While some argue that these medications can help remove the moral judgment associated with obesity and offer a medical solution to a chronic condition, others worry that they may reinforce societal expectations of thinness and create new layers of stigma for those who cannot or choose not to use them. As the pharmaceutical industry continues to develop and approve more weight loss drugs, it's crucial to consider the potential psychological and cultural implications, including the impact on individuals' relationships with food and their bodies, as well as the broader societal conversations around weight and health. Ultimately, it's essential to approach this issue with a nuanced understanding of the complex interplay between personal choice, medical intervention, and societal expectations.

    • Impeachment trial of Texas AG Ken Paxton tests GOP loyaltyDespite serious allegations, Republican officials faced intense pressure to acquit Texas AG Ken Paxton during his impeachment trial, highlighting the challenges of using impeachment to oust a sitting GOP figure.

      The impeachment trial of Texas Attorney General Ken Paxton served as a test of Republican Party loyalty during the hyperpartisan era of Donald Trump. Paxton, a Trump ally, was impeached by the Republican-controlled Texas House over allegations of office abuse, but was acquitted by the Texas Senate this weekend amid intense pressure from national conservatives. The trial highlighted the challenges of using the impeachment process to oust a sitting Republican official, even in the face of serious allegations. The episode was produced by Nina Feldman and Alex Stern, edited by Lexi Diao, fact checked by Susan Lee, and engineered by Alissa Moxley, with original music by Marion Lozano, Rowan Emisto, Diane Wong, and Alicia Batitub. Our theme music is by Brunsberg and Ben Landsberg of Wonderlane.

    Recent Episodes from The Daily

    France’s Far Right at the Gates of Power

    France’s Far Right at the Gates of Power

    The far right in France had a big win this month, crushing the party of President Emmanuel Macron in elections for the European Parliament. But the results did not affect France’s government at home — until Mr. Macron changed that.

    Roger Cohen, the Paris bureau chief for The Times, discusses the huge political gamble Mr. Macron has taken, which has brought the far right closer than ever to gaining real power in France.

    Guest: Roger Cohen, the Paris bureau chief for The New York Times.

    Background reading: 

    • Battered by the far right in voting for the European Parliament, Emmanuel Macron called for new elections in France.
    • The president has challenged voters to test the sincerity of their support for the far right. Were the French letting off steam in the European elections, or did they really mean it?

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

    The Daily
    enJune 26, 2024

    The Plan to Defeat Critics of Israel in Congress

    The Plan to Defeat Critics of Israel in Congress

    A powerful group supporting Israel is trying to defeat sitting members of Congress who have criticized the country’s deadly war against Hamas.

    Nicholas Fandos, who covers New York politics for The Times, explains why it appears that strategy may work in today’s Democratic primary in New York.

    Guest: Nicholas Fandos, who covers New York politics and government for The New York Times.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

    The Daily
    enJune 25, 2024

    The Army of Poets and Students Fighting a Forgotten War

    The Army of Poets and Students Fighting a Forgotten War

    Warning: this episode contains descriptions of injuries.

    Myanmar is home to one of the deadliest, most intractable civil wars on the planet. But something new is happening. Unusual numbers of young people from the cities, including students, poets and baristas, have joined the country’s rebel militias. And this coalition is making startling gains against the country’s military dictatorship.

    Hannah Beech, who covers stories across Asia for The Times, discusses this surprising resistance movement.

    Guest: Hannah Beech, a Bangkok-based reporter for The New York Times, focusing on investigative and in-depth stories in Asia.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

    The Daily
    enJune 24, 2024

    'Animal,' Episode 4: Ferrets

    'Animal,' Episode 4: Ferrets

    In a broken world, what can we gain by looking another animal in the eye? "Animal" is a six-part, round-the-world journey in search of an answer. In Episode 4, the writer Sam Anderson soothes his anxiety by visiting a convention center in Ohio.

    For photos and videos of Sam's adventure with manatees, visit nytimes.com/animal.

    The Daily
    enJune 23, 2024

    America’s Top Doctor on Why He Wants Warning Labels on Social Media

    America’s Top Doctor on Why He Wants Warning Labels on Social Media

    Warning: This episode contains mentions of bullying and suicide.

    A rising tide of mental health problems among teenagers has sent parents, teachers and doctors searching for answers. This week, the U.S. surgeon general, Dr. Vivek H. Murthy, offered one: social media.

    Today, Dr. Murthy discusses his proposal to require platforms such as YouTube, TikTok and Instagram to include warning labels, like those that appear on tobacco and alcohol products.

    Guest: Dr. Vivek H. Murthy, the U.S. surgeon general.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

    The Daily
    enJune 21, 2024

    The Mysterious Gun Study That’s Advancing Gun Rights

    The Mysterious Gun Study That’s Advancing Gun Rights

    In the battle to dismantle gun restrictions, raging in America’s courts even as mass shootings become commonplace, a Times’ investigation has found that one study has been deployed by gun rights activists to notch legal victories with far-reaching consequences.

    Mike McIntire, an investigative reporter for The Times, discusses the study and the person behind it.

    Guest: Mike McIntire, an investigative reporter at The New York Times.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. 

    The Daily
    enJune 20, 2024

    A Novel Legal Strategy for Mass Shooting Victims’ Families

    A Novel Legal Strategy for Mass Shooting Victims’ Families

    As mass shootings plague the United States, victims’ families continue to search for accountability. To that end, a pair of lawsuits by the families of victims of the Uvalde school shooting will try a new tactic.

    J. David Goodman, the Houston bureau chief for The Times, discusses the unusual targets of the lawsuits and profiles the lawyers behind them.

    Guest: J. David Goodman, the Houston bureau chief for The New York Times.

    Background reading: 

    • The Uvalde lawsuits are among the most far-reaching to be filed in response to the escalating number of mass shootings in the United States.

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

    The Daily
    enJune 18, 2024

    Abortion United Evangelicals and Republicans. Now That Alliance Is Fraying.

    Abortion United Evangelicals and Republicans. Now That Alliance Is Fraying.

    The Southern Baptist Convention, the largest denomination of Protestant Christians in the United States, voted at an annual gathering last week to oppose the use of in vitro fertilization.

    Ruth Graham, who covers religion, faith and values for The New York Times, discusses the story behind the vote, the Republican scramble it prompted and what it could eventually mean for the rest of the country.

    Guest: Ruth Graham, who covers religion, faith and values for The New York Times.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. 

    The Daily
    enJune 17, 2024

    'Animal,' Episode 3: Manatees

    'Animal,' Episode 3: Manatees

    In a broken world, what can we gain by looking another animal in the eye? "Animal" is a six-part, round-the-world journey in search of an answer. In Episode 3, the writer Sam Anderson travels to Florida to fulfill a lifelong dream: to swim with manatees.

    For photos and videos of Sam's adventure with manatees, visit nytimes.com/animal.

    The Daily
    enJune 16, 2024

    Related Episodes

    Ozempic

    Ozempic

    Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?

    Links: 

    Thanks to Doctor Dreamchip for our lovely theme song!

    Support the show

    JP Morgan Healthcare Conference Highlights

    JP Morgan Healthcare Conference Highlights
    Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” into making new molecules. - How NVIDIA could change drug development.  - Moderna’s vaccine strategy Companies discussed: LLY, NVO, GPCR, NVDA, DXCM, NVDA, BIIB, GEHC, MRNA, NVCR, VRTX Host: Deidre Woollard Guest: Karl Thiel Producer: Ricky Mulvey Engineer: Tim Sparks Learn more about your ad choices. Visit megaphone.fm/adchoices

    Here's How the New Weight Loss Drugs Could Change Everything

    Here's How the New Weight Loss Drugs Could Change Everything

    There's a new class of weight-loss drugs in town. GLP-1 medications including Ozempic, Wegovy and Mounjaro were created to treat diabetes but have since been found to suppress appetites and induce substantial weight loss. It's a big deal for the companies which make them, with shares of Novo Nordisk and Eli Lilly all soaring in recent weeks. But the drugs could end up having a much broader economic impact too. On this episode, we speak with James van Geelen of Citrinitas Capital, about the second-order effects of effective weight-loss drugs. He talks us through how he's evaluating the potential of the new meds and how he approaches possible 'mega-trends' like GLP-1 or AI.

    See omnystudio.com/listener for privacy information.

    How the Rise of Ozempic Will Affect the Food Industry

    How the Rise of Ozempic Will Affect the Food Industry

    Today I’m deep-diving on all things GLP-1 agonist medications and forecasting their impact on the CPG food and beverage industry for 2024 and beyond. Specifically, I discuss: 

    • How GLP-1’s change individuals’ food preferences, overall intake, and alter taste perception 

    • How the rise of GLP-1’s as the pharmaceutical industry’s “blockbuster” might affect the food industry in the short and long-term, and how food companies could start to approach this topic as they prepare their product roadmaps for the future

    • What are some specific concerns among individuals taking GLP-1’s as it relates to food and beverage products, and their own personal tolerance to specific foods in light of medication side effects?

    • GLP-1’s and early satiety: We discuss how the medications create feelings of early satiety– what this means for practitioners, how this affects individual patients, and how the MNT for GERD and early satiety may be beneficial when considering / seeking to understand this patient population more effectively

    • Alcohol, coffee, single-serve convenience foods, sugar-sweetened beverages, tomato-based products, eggs, veggies and fruit, and high saturated fat, high refined carb food products– what do all of these products have in common, and which ones of these will be better tolerated by individuals taking GLP-1’s vs. not

    • Side effects of GLP-1’s that affect diet and lifestyle, and how these translate to CPG foo and beverage industries and product roadmaps/financial forecasting 

    • My most fascinating finding of all: How tolerance to GLP-1 medications may be promoted through nutrition education & adopting diet & lifestyle shifts BEFORE STARTING the medication vs. referring to a dietitian/receiving nutrition education AFTER starting a GLP-1. I talk about why the lack of nutrition education & counseling may be affecting medication tolerance and ultimately, affecting a patient’s ability to adhere to the medication long-term due to diet-related side effects.

    • The foods & beverages NOT AFFECTED by GLP-1’s that still demand attention for the sake of helping individuals achieve better cardiometabolic health. 

     

    🎙️Follow The Business of Wellness on Apple Podcasts & leave a 5-star rating & review 

    🎙️Hire me to consult before you invest in or get to work on that “better-for-you” product  

    🎙️Follow me @jaclynlondonrd

    🎙️Krispy Kreme article from Forbes

    🎙️Are GLP-1’s the root cause of consumer shopping shifts? WaPo thinks so (but I’m not sold)

     

    Advice provided on this podcast should not replace medical advice provided by your physician. 

    How the Rise of Ozempic Will Affect the Food Industry

    How the Rise of Ozempic Will Affect the Food Industry

    Today I’m deep-diving on all things GLP-1 agonist medications and forecasting their impact on the CPG food and beverage industry for 2024 and beyond. Specifically, I discuss: 

    • How GLP-1’s change individuals’ food preferences, overall intake, and alter taste perception 

    • How the rise of GLP-1’s as the pharmaceutical industry’s “blockbuster” might affect the food industry in the short and long-term, and how food companies could start to approach this topic as they prepare their product roadmaps for the future

    • What are some specific concerns among individuals taking GLP-1’s as it relates to food and beverage products, and their own personal tolerance to specific foods in light of medication side effects?

    • GLP-1’s and early satiety: We discuss how the medications create feelings of early satiety– what this means for practitioners, how this affects individual patients, and how the MNT for GERD and early satiety may be beneficial when considering / seeking to understand this patient population more effectively

    • Alcohol, coffee, single-serve convenience foods, sugar-sweetened beverages, tomato-based products, eggs, veggies and fruit, and high saturated fat, high refined carb food products– what do all of these products have in common, and which ones of these will be better tolerated by individuals taking GLP-1’s vs. not

    • Side effects of GLP-1’s that affect diet and lifestyle, and how these translate to CPG foo and beverage industries and product roadmaps/financial forecasting 

    • My most fascinating finding of all: How tolerance to GLP-1 medications may be promoted through nutrition education & adopting diet & lifestyle shifts BEFORE STARTING the medication vs. referring to a dietitian/receiving nutrition education AFTER starting a GLP-1. I talk about why the lack of nutrition education & counseling may be affecting medication tolerance and ultimately, affecting a patient’s ability to adhere to the medication long-term due to diet-related side effects.

    • The foods & beverages NOT AFFECTED by GLP-1’s that still demand attention for the sake of helping individuals achieve better cardiometabolic health. 

     

    🎙️Follow The Business of Wellness on Apple Podcasts & leave a 5-star rating & review 

    🎙️Hire me to consult before you invest in or get to work on that “better-for-you” product  

    🎙️Follow me @jaclynlondonrd

    🎙️Krispy Kreme article from Forbes

    🎙️Are GLP-1’s the root cause of consumer shopping shifts? WaPo thinks so (but I’m not sold)

     

    Advice provided on this podcast should not replace medical advice provided by your physician.